• Langley Road, Brighton, MA
  • 416-402-8274

Stemina Cardiotoxicity Screening

One Million Solutions in Health’s Technology Evaluation Consortium™ Evaluated the Stemina Cardiotoxicity Screening as INNOVATOR in its Signature Square™ Program
The designation of Innovator was bestowed upon Stemina’s Cardiotoxicity Screening technology via the One Million Solutions in Health Signature Square™ program after an evaluation by members of the Technology Evaluation Consortium.

The One Million Solutions in Health™ Technology Evaluation Consortium™ designated the Stemina Cardiotoxicity Screening as Innovator technology through its Signature Square™ program in late 2015. This innovative technology from Stemina in Madison, Wisconsin is a test based on a human cellular system that screens compounds for the potential to cause a variety of types of cardiotoxicity, with an emphasis on cardiomyopathy.

The Signature Square program provides feedback to technology or service providers (commercial, academic, government, healthcare institutions, etc.) based on confidential reviews by Subject Matter Experts in the life sciences and health care sectors for new or established solutions.

The consortium members independently chose to review this technology and evaluate its role and usefulness in drug safety. Based on their analysis and ratings, the consortium members provided a designation for this solution: Stemina Cardiotoxicity Screening as Innovator.

Stemina’s assay is a test based on human cellular systems. It screens compounds for the potential to cause a variety of types of cardiotoxicity, with an emphasis on cardiomyopathy. The Stemina metabolomics platform is integrated to utilize a wide array of biological materials using highly sensitive liquid chromatography and mass spectrometry.

The highly complex data is normalized and processed using sophisticated metabolomic uni-variate and multi-variate methods. Stemina delivers: Biomarker Discovery, Biomarker Validation, Predictive Toxicology and Biological Pathway Analysis. The screening model is built using a set of 24 pharmaceutical agents of known cardiotoxicity. The cardiotoxic compounds come from different compound classes that cause a variety of types of cardiotoxicity, including cardiomyopathy and QT prolongation.

“We are pleased to have hosted another Signature Square event,” Dawn Van Dam, President and CEO of One Million Solutions in Health stated. “Our goal is to bring experts from around the world together in order to accelerate the development of new scientific technology and allow the industry and the vendors/scientists to apply the feedback they gain in order to improve scientific discovery.”

All technologies rated through the Signature Square process are given a designation in one of the four potential technology or service categories: Blockbuster, Novel, Upstart or Innovator. The rating for theStemina Cardiotoxicity Screening as Innovator was provided via the evaluation by Subject Matter Experts from around the world. The Signature Square evaluation occurs on two dimensions: 1) Value Proposition to the Marketplace and 2) Market or Partner Readiness.

A One Million Solutions in Health Signature Square evaluation is an opportunity for technology or service providers to receive direct evaluations and feedback which can then be used to inform potential investors, end users and/or partners. It can also be utilized as a component towards understanding the technology or service and its potential to contribute to health care.

The Subject Matter Experts are members of the Technology Evaluation Consortium with specific expertise in the relevant area for each technology, including individuals from top biopharmaceutical, diagnostic, device, health data or healthcare organizations in the field, as relevant. One Million Solutions in Health aims to have a broad representation of feedback and advice from relevant Subject Matter Experts in each area. These experts evaluate the technology or service such that the feedback received is valid and valuable.

The positioning within the Signature Square is related to the aforementioned criteria, along with the point-in-time at which it has been evaluated. Consequently, a technology evaluated early could be considered an Innovator, but by addressing the feedback received in the process, could eventually be considered a Blockbuster.

For an opportunity to join the Technology Evaluation Consortium, and review the detailed information, video and evaluation for this technology: Stemina Cardiotoxicity Screening as Innovator, please contact Dawn Van Dam at One Million Solutions in Health (dawn.vandam@onemillionsolutionsinhealth.org).


The goal of One Million Solutions in Health™ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery … of innovative cures, treatments and preventative measures for patients around the world.

In this next year, we will be reviewing 1000’s of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.

We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research and share patient and consumer-focused ideas and solutions.

As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!


The Technology Evaluation Consortium™ from One Million Solutions in Health™ is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.

The model empowers technology providers/scientists and industry end-users to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry and to be the place for the industry to conduct their evaluations and validations.


Stemina Biomarker Discovery was established in November 2006 and was founded by Elizabeth Donley, JD, MBA, MS and Gabriela Cezar, DVM, PhD. Stemina’s technology arises from the pioneering work of Dr. Cezar at the University of Wisconsin, Madison, on the strategic convergence of two cutting-edge technologies: stem cells and metabolomics. The company’s first commercial product was launched at the March 2009 Society of Toxicology meeting held in Washington D.C. This drug screening service uses human embryonic stem cells to screen drugs, chemicals, consumer products and cosmetics for their potential effect on the developing human embryo. The team has grown by adding very skilled staff and continues to expand with newer efforts directed towards the discovery of novel diagnostic biomarkers with projects in autism, cancer, and reproductive biology. http://www.stemina.com